EMBOLEX Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Embolex, and what generic alternatives are available?
Embolex is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in EMBOLEX is dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride. There are six drug master file entries for this compound. Additional details are available on the dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for EMBOLEX?
- What are the global sales for EMBOLEX?
- What is Average Wholesale Price for EMBOLEX?
Summary for EMBOLEX
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 131 |
Clinical Trials: | 1 |
Patent Applications: | 4,090 |
Formulation / Manufacturing: | see details |
DailyMed Link: | EMBOLEX at DailyMed |
![EMBOLEX drug patent expirations Drug patent expirations by year for EMBOLEX](/p/graph/s/t/EMBOLEX-patent-expirations.png)
Recent Clinical Trials for EMBOLEX
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Novartis | Phase 3 |
US Patents and Regulatory Information for EMBOLEX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | EMBOLEX | dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride | INJECTABLE;INJECTION | 018885-001 | Nov 30, 1984 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Novartis | EMBOLEX | dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride | INJECTABLE;INJECTION | 018885-002 | Nov 30, 1984 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for EMBOLEX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novartis | EMBOLEX | dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride | INJECTABLE;INJECTION | 018885-001 | Nov 30, 1984 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | EMBOLEX | dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride | INJECTABLE;INJECTION | 018885-002 | Nov 30, 1984 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | EMBOLEX | dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride | INJECTABLE;INJECTION | 018885-001 | Nov 30, 1984 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | EMBOLEX | dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride | INJECTABLE;INJECTION | 018885-002 | Nov 30, 1984 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for EMBOLEX
See the table below for patents covering EMBOLEX around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | H021126 | ⤷ Sign Up | |
France | 2478101 | ⤷ Sign Up | |
Hong Kong | 40386 | STABLE SOLUTIONS OF HYDROGENATED ERGOTALKALOIDS | ⤷ Sign Up |
Japan | S5692288 | NOVEL ANTIBIOTIC MITOMYCIN COMPOUND*DRUG MIXTURE CONTAINING IT FOR TREATING ANIMAL TUMOR AND TREATMENT FOR ANIMAL TUMOR | ⤷ Sign Up |
Belgium | 886008 | ⤷ Sign Up | |
Japan | S5686116 | STABLE SOLUTION OF HYDROGENATED ERGOT ALKALOIDS | ⤷ Sign Up |
South Africa | 8007005 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |